Al­ler­gan taps Catal­en­t's Matthew Walsh as CFO; Re­Vi­ral meets end­points in PhI­Ia RSV tri­al

→ Af­ter a months-long hunt, Al­ler­gan $AGN has locked in Matthew Walsh as the suc­ces­sor of out­go­ing CFO Maria Tere­sa Hi­la­do, who an­nounced the de­sire to re­tire in Sep­tem­ber. Most re­cent­ly CFO at out­sourc­ing com­pa­ny Catal­ent, Walsh — al­so named EVP — is tasked with un­lock­ing growth po­ten­tial even as Al­ler­gan con­tends with the im­mi­nent gener­ic com­pe­ti­tion fac­ing its Resta­sis fran­chise. “Matt brings to Al­ler­gan a unique com­bi­na­tion of skills, in­clud­ing a tech­ni­cal back­ground, a deep un­der­stand­ing of the health­care in­dus­try, a rich ex­pe­ri­ence across fi­nan­cial dis­ci­plines, and the abil­i­ty to lead com­plex health care or­ga­ni­za­tions,” said CEO Brent Saun­ders in a state­ment. “I’m pleased to wel­come Matt to our team and look for­ward to part­ner­ing with him as we con­tin­ue to dri­ve strong fi­nan­cial per­for­mance and de­ploy our cap­i­tal to in­crease share­hold­er re­turn over the short- and long-term.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER